BEAM

Beam Therapeutics Inc.
CAPPED RATING

Beam Therapeutics is a biotechnology company committed to establishing the leading, fully integrated platform for precision genetic medicines. To achieve this vision, Beam has assembled a platform that includes a suite of gene editing and delivery technologies and is in the process of building internal manufacturing capabilities. Beam\'s suite of gene editing technologies is anchored by base editing, a proprietary technology that enables precise, predictable and efficient single base changes, at targeted genomic sequences, without making double-stranded breaks in the DNA. This enables a wide range of potential therapeutic editing strategies that Beam is using to advance a diversified portfolio of base editing programs. Beam is a values-driven organization committed to its people, cutting-edge science, and a vision of providing life-long cures to patients suffering from serious diseases.

Beam Therapeutics Inc. (BEAM) is rated C (2.2/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Value (B-); its weakest is Growth (D-). The rating has held at C for 8 weeks.

Quantitative Factor Evaluation • Updated

Overall Rating
2.2 / 5.0
C
Value
B-
Factor Score 2.9 / 5.0
Growth
D-
Factor Score 0.9 / 5.0
Profitability
C
Factor Score 2.3 / 5.0
Momentum
C
Factor Score 2.5 / 5.0
Revisions
C+
Factor Score 2.6 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio -4.2
EV / EBITDA -3.5
Rev Growth YoY -96.8%
Gross Margin N/M
Price Return 3M -21.2%
Price Return 12M -3.3%
Catalyst Signal 0.00
Market Cap $2.2B
TTM Revenue $146.6M
Price / Sales 14.8
ROE -11.3%

Historical Factor Score Progression

Held C for 8 weeks
Date Value Growth Profitability Momentum Revisions Overall
2026-11-17 B- (2.9) D- (0.9) C (2.3) C (2.5) C+ (2.6) C (2.2)
2026-11-10 B- (2.9) D- (1.0) C (2.3) C+ (2.8) C+ (2.6) C (2.3)
2026-11-03 B- (2.9) D (1.3) C (2.3) C (2.5) C+ (2.7) C (2.3)
2026-10-27 B- (2.9) D (1.4) C (2.3) C (2.2) C+ (2.6) C (2.3)
2026-10-20 B- (2.9) D (1.5) C (2.3) C (2.2) C+ (2.6) C (2.3)
Page 1 of 8
…